loading page

Can procalcitonin be a new biomarker in prostate cancer? Preliminary results
  • Abdullah Ilktac,
  • Senad Kalkan,
  • Selahattin Çalışkan
Abdullah Ilktac
Bezmialem Vakif Universitesi Tip Fakultesi

Corresponding Author:abdullahilktac@hotmail.com

Author Profile
Senad Kalkan
Bezmialem Vakif Universitesi Tip Fakultesi
Author Profile
Selahattin Çalışkan
Reyap Special Hospital
Author Profile


Aim: Prostate cancer (PCa) is one of the most common cancer among men in the world. Prostate specific antigen is the most used biomarker for PCa diagnosis. In this study we aimed to measure the procalcitonin(PCT) and C-reactive protein (CRP) levels in patients with PCa. Methods: The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses. Results: The current study includes 149 patients. There were 118 patients in group1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels was 3.33 and 0.01 in group 4.07 and 0.04 in group 2. Serum PCT levels was significantly higher in patients with PCa. Conclusion: We found that elevated procalcitonin levels was associated with prostate cancer. Further studies are needed to define the relationship between procalcitonin and prostate cancer. What’s Known: Prostate cancer is the second most common cancer among elderly men. Prostate specific antigen testisng is usually used in screening and diagnosis. Unfortunately PSA is not cancer specific and new biomarkers are needed for prostate cancer management. What’s New: Procalcitonin is a precursor of calcitonin which is produced by thyroid C-cells and some neuroendocrine cells. The elevated level of procalcitonin is associated with bacteremia and sepsis. In this study e investigated the procalcitonin levels in prostate cancer.
30 May 2020Submitted to International Journal of Clinical Practice
08 Jun 2020Submission Checks Completed
08 Jun 2020Assigned to Editor
25 Jun 2020Reviewer(s) Assigned
24 Jul 2020Review(s) Completed, Editorial Evaluation Pending
24 Jul 20201st Revision Received
28 Jul 2020Submission Checks Completed
28 Jul 2020Assigned to Editor
13 Aug 2020Reviewer(s) Assigned
19 Nov 2020Review(s) Completed, Editorial Evaluation Pending
20 Nov 2020Editorial Decision: Accept